Flightpath Biosciences - Crunchbase Company Profile & Funding

Q: Who invested in Flightpath Biosciences?

Flightpath Biosciences has 3 investors including Ann Arbor SPARK And Michigan Rise.

Q: How much funding has Flightpath Biosciences raised to date?

Flightpath Biosciences has raised obfuscated.

Overview

Flightpath Biosciences

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Flightpath Biosciences

CB Rank

70526

Flightpath Biosciences is a biotechnology company that develops medications to treat rare infectious diseases.

Founded

obfuscation

Private

Seed

Berkeley, California, United States

1-10

flightpath.bio/

Biotechnology

Health Care

Life Science

Therapeutics

Funding Rounds

Seed

OBF

obfuscation

Series A

OBF

obfuscation

Seed

OBF

obfuscation

Key People

Matthew Tindall: CEO and Founder
Past Role: Fabric Genomics (formerly Omicia), Chief Executive Officer
Curtis Scribner: Co-Founder, Chief Medical Officer and Head of Clinical and Regulatory

Details

Legal Name

Flightpath Biosciences, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Curtis Scribner, Mark De Souza, Matthew Tindall

About the Company

Flightpath Biosciences is a biotechnology company that develops medications to treat rare infectious diseases.

The company is bridging scientific unknowns by interrogating disparate fields of biology, taking risks, innovating, and deploying potentially orthogonal approaches to achieve desired outcomes. It is working with leading scientists,

therapeutics, and diagnostics experts across multiple scientific disciplines within several esteemed academic institutions and government agencies to create novel, targeted solutions.

The company was founded in 2019 and is based in Berkeley, California.

Phone Number

415-530-1828

Predictions & Insights

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

FP-100 (Lyme Disease)

An orally available narrow-spectrum antibiotic targeting Borrelia burgdorferi, the primary pathogen responsible for Lyme disease.

FP-100 (Cancer)

An orally available narrow-spectrum antibiotic targeting Fusobacterium nucleatum, associated with colorectal cancer (CRC) and oral squamous cell carcinoma (OSCC).

Research & Development

Flightpath Biosciences is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed
obfuscated obfuscation	Seed Round - Flightpath Biosciences	—	obfuscated obfuscation	—	Seed

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Ann Arbor SPARK	—	Series A - Flightpath Biosciences	Mike Flanagan
Ann Arbor SPARK	—	Series A - Flightpath Biosciences	Mike Flanagan
Ann Arbor SPARK	—	Series A - Flightpath Biosciences	Mike Flanagan
Ann Arbor SPARK	—	Series A - Flightpath Biosciences	Mike Flanagan
Ann Arbor SPARK	—	Series A - Flightpath Biosciences	Mike Flanagan

Market Intelligence

People

View Profiles & Contacts

Headcount

1-10

Employee Profiles

Contacts

Employee Profiles

Matthew Tindall CEO and Founder
Curtis Scribner Co-Founder, Chief Medical Officer and Head of Clinical and Regulatory
Mark De Souza Co-FOunder and Executive Chairman